Q1 2026 Hong Kong Market Update
Apr 29, 2026

This Q1 2026 round-up summarises key trading and fundraising indicators in what was a robust start to the year across Hong Kong’s primary and secondary markets. All figures are sourced from HKEX market statistics unless otherwise stated.

 

Q1 2026 Market Highlights
  • Cash market ADT: HK$276.7 billion, up 14% year-on-year
  • Derivatives ADT: 1.83 million contracts, down 1.7% year-on-year
  • ETF ADT: HK$40.2 billion, up 15% year-on-year
  • Number of IPOs: 40, compared with 17 in Q1 2025
  • Total funds raised via IPOs: HK$110.4 billion, compared with HK$18.7 billion in Q1 2025

 


Robust cash market turnover continued into 2026

Average daily turnover (ADT) in Hong Kong’s cash equities market reached HK$276.7 billion in Q1 2026, representing a year-on-year increase of 14%. Q1 closed out strongly, with ADT for March reaching HK$304.0 billion.

 

hong kong cash market adt 2024 2026 e3

Hong Kong maintains position as the world’s no. 1 IPO venue

Hong Kong maintained its position as the world’s top IPO venue by funds raised in Q1 2026.

Forty new listings raised HK$110.4 billion – the second-highest Q1 fundraising volume recorded by HKEX – with notable individual raises by Muyuan Foods, Eastroc and Montage.

TMT was the dominant sector in the Hong Kong IPO market in Q1 2026, with notable activity by companies from across the AI value chain.

Hong Kong saw eight of the 10 largest TMT IPOs globally in the quarter, and total fundraising by companies in the sector accounted for 55% of total fundraising during the quarter. Looking ahead, there is a healthy pipeline of listing candidates, including eight international companies.


ECM fundraising hits five-year Q1 high
Total ECM fundraising remained strong in Q1 2026, reaching US$30.6 billion, up 45% year-on-year, according to Dealogic data, and the highest Q1 total in five years. The quarter saw a mix of IPOs and follow-on deals. Follow-on issuance totalled US$17.3 billion, including several large-scale convertible bond offerings and share placements.

Q1 2026 Connect trading volumes exceeded records set in 2025
In Q1 2026, Stock Connect flows hit record highs, with Southbound ADT up 11.5% year-on-year to HK$122.5 billion and Northbound ADT surging 69.6% year-on-year to RMB324.1 billion. Trading activity on both channels exceeded the record levels posted in FY 2025.

Chinese Mainland investors drove over HK$220 billion in net Southbound inflows, fueled by strong retail demand for tech and consumer names. Northbound activity was led by global institutions targeting A-share growth sectors like new energy and semiconductors.

Southbound trading and product innovation drove Hong Kong’s ETP market in Q1
  • ETP ADT: HK$45.1 billion, up 14% year-on-year
  • ETF ADT: HK$40.2 billion, up 15% year-on-year
  • Southbound ETF ADT: HK$7.1 billion, up 60% year-on-year
  • Northbound ETF ADT: RMB4.8 billion, up 50% year-on-year
  • L&I ADT: HK$4.9 billion, up 11% year-on-year

Hong Kong’s ETP market recorded higher average daily turnover in Q1 2026, supported by Southbound activity and strong traction for new products launched in the past two years.

Covered call ETFs, launched in February 2024, reached HK$681 million in ADT – approximately 27 times the level recorded a year earlier – while single-stock Leveraged and Inverse (L&I) products, introduced in March 2025, saw ADT exceed HK$2.3 billion, a five-fold increase.


Vibrancy builds in Asia’s risk management hub

Derivatives trading remained active in Q1 2026, averaging 1.83 million contracts a day, exceeding FY 2025 ADV of 1.66 million. Demand for hedging amid geopolitical uncertainty and heightened volatility drove ADV to 2 million contracts in March.

 

hongkong_derivs_eng_ver2

 

Equity index futures averaged 690,722 contracts per day, a marginal 0.1% decline year-on-year, while equity index options saw a notable uptick, rising 21% to 158,009 contracts daily – Hang Seng TECH Index Futures Options saw record high daily volume on 4 February 2026, according to HKEX data.


Biotech Futures gain traction

Hang Seng Biotech Index Futures hit a record high of 1,239 contracts on 27 March 2026, according to HKEX data.

These contracts – launched in November 2025 – are gradually gaining traction as market participants look for ways to manage exposure to Hong Kong’s biotech ecosystem.

 

HKBIOMar2026e_ver2


Geopolitical uncertainty was prevalent through Q1 2026 but Hong Kong’s financial markets continued to demonstrate resilience across equities, derivatives and market infrastructure during the quarter.

Q2 2026 started with brisk trading and fundraising activity amid continued engagement across multiple market segments. With a healthy IPO pipeline, plus further market enhancements and an expanding product ecosystem in prospect, we look forward to continued momentum through the quarter and throughout 2026.